We hypothesized that CDK2-mediated site-specific phosphorylation of EZH2 drives tumorigenesis and contributes to TNBC phenotype, and inhibition of CDK2/EZH2 axis by specific inhibitors may reverse the phenotypes, thereby rendering TNBC targetable by current breast cancer therapies. This evidence concerns the gene CDK2 and breast carcinoma.